REGULATORY

Chuikyo Subcommittee Roughly OKs Sakigake Pricing Premium, Yet No Agreement on Rate Raise

October 15, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A drug pricing subcommittee of the Central Social Insurance Medical Council (Chuikyo) on October 14 basically agreed to revamp a now-dormant pricing premium designed to reward the development of first-in-class medicines in Japan by connecting it with the so-called “sakigake”…

To read the full story

Chuikyo Payer Reps Wary of Revising Foreign Price Adjustment Rule for Govt-Requested Drugs
October 15, 2015
Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015

REGULATORY

AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
Daiichi, University of Tokyo Professor Win Japan’s PM Award for Ezharmia Development
January 20, 2026
Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…